Authors: Nguyễn Thị Thu Thủy1, Đỗ Văn Dũng2, Phạm Mạnh Hùng3, Bùi Minh Trạng4, Nguyễn Chí Thanh4, Lê Diễm Quỳnh5
1.HongBang International University.
2.Ho Chi Minh University of Medicine and Pharmacy.
3.Vietnam National Heart Institute – Bach Mai Hospital.
4.Ho Chi Minh Heart Institute.
5.Health Technology Assessment and Application Research Institute.
Objectives: Cost-effectiveness analysis of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) for treatment of heart failure with reduced ejection fraction (HFrEF) in Vietnam.
Research methods: Modeling using Markov model for cost-effectiveness analysis in payer perspective. Collecting input parameters using systematic review, retrospective health insurance payment data at hospitals in Ha Noi and Ho Chi Minh city, and consultation of clinical experts.
Results: Sacubitril/valsartan resulted in an increase of 0.50 QALY and 0.59 LYG compared to ACEIs; and increase total costs by 65.8 to 74.4 million VND. Incremental cost-effectiveness ratio (ICER) for sacubitril/valsartan ranged from 132.7 to 149.6 million VND/QALY compared to ACEIs. Mortality rate and quality of life coefficient most influence on the ICER value and the probability that sacubitril/valsartan is cost-effective compared to enalapril in the treatment of HFrEF is 90%.
Conclusion: From payer perspective, with the 1-3 times GDP-per-capita willingness-to-pay threshold, sacubitril/valsartan is cost-effective compared to ACEIs in the treatment of HfrEF.
Source: Vietnam Medical Journal.
Doi: https://doi.org/10.51298/vmj.v527i1B.5759.